Coskun, AbdurrahmanAarsand, Aasne K.Sandberg, SverreGuerra, ElenaLocatelli, MassimoDiaz-Garzon, JorgeFernandez-Calle, PilarCeriotti, FerruccioJonker, NielsBartlett, William A.Carobene, AnnaChem, European Federation Clinical2023-02-212023-02-212022-01-0110.1515/cclm-2021-0283https://hdl.handle.net/11443/2674http://dx.doi.org/10.1515/cclm-2021-0283Objectives: Reliable biological variation (BV) data are required for the clinical use of tumor markers in the diagnosis and monitoring of treatment effects in cancer. The European Biological Variation Study (EuBIVAS) was established by the EFLM Biological Variation Working Group to deliver BV data for clinically important measurands. In this study, EuBIVAS-based BV estimates are provided for cancer antigen (CA) 125, CA 15-3, CA 19-9, carcinoembryonic antigen, cytokeratin-19 fragment, alpha-fetoprotein and human epididymis protein 4. Methods: Subjects from five European countries were enrolled in the study, and weekly samples were collected from 91 healthy individuals (53 females and 38 males21-69 years old) for 10 consecutive weeks. All samples were analyzed in duplicate within a single run. After excluding outliers and homogeneity analysis, the BVs of tumor markers were determined by CV-ANOVA on trendcorrected data, when relevant (Roraas method). Results: Marked individuality was found for all tumor markers. CYFRA 21-1 was the measurand with the highest index of individuality (II) at 0.67, whereas CA 19-9 had the lowest II at 0.07. The CVIs of HE4, CYFRA 21-1, CA 19-9, CA 125 and CA 15-3 of pre- and postmenopausal females were significantly different from each other. Conclusions: This study provides updated BV estimates for several tumor markers, and the findings indicate that marked individuality is characteristic. The use of reference change values should be considered when monitoring treatment of patients by means of tumor markers.biological variationcancertumor markersArticleWOS:000737400200001